Cboe Extends IPO Wait Times for Shaky Derivatives
Published Date: 9/17/2025
Notice
Summary
Cboe BZX Exchange is updating its rules to clearly say it can extend the 'quote-only' period during an IPO auction if a new derivative security doesn’t meet listing requirements. This change helps the Exchange manage IPOs better and keeps things fair for traders. It’s effective immediately, so anyone involved in IPO auctions on Cboe BZX should take note!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
BZX can pause IPO auctions for derivative listing issues
If you trade or plan to trade in IPO auctions on the Cboe BZX Exchange, the Exchange amended Rule 11.23 to explicitly allow it to extend the Quote-Only Period for an IPO Auction when a Derivative Security fails to meet the Exchange's listing qualification requirements in Rule 14.11. The change was filed on September 3, 2025 and the SEC waived the normal 30-day delay, so the amendment is operative upon filing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12163, The Trade-Through Rule and Locked and Crossed Markets Provisions of Regulation NMS
The SEC wants to scrap some old rules that stop stocks from being traded at worse prices and prevent confusing market quotes. This change affects stock traders and exchanges, aiming to simplify trading and possibly speed things up. If you want to share your thoughts, you’ve got until August 17, 2026, so don’t miss out!
2026-10373, Registered Offering Reform
The SEC wants to make it easier and cheaper for more companies to sell their stocks and bonds to the public. They’re opening up special forms and benefits to more businesses, updating rules to be more modern, and cutting red tape by overriding some state rules. If you’re a company planning to raise money, these changes could speed things up and save you money, with feedback due by July 27, 2026.
2026-10222, Enhancement of Emerging Growth Company Accommodations and Simplification of Filer Status for Reporting Companies
The SEC is making it easier for companies that report their finances by simplifying their categories into just two groups: big and small filers. Smaller companies, including emerging growth ones, will get more time to file reports and enjoy simpler rules, while big companies keep stricter standards. These changes aim to save time and money, with feedback open until July 20, 2026.
2026-07651, Concept Release on Consolidated Audit Trail and Other Audit Trails and Data Sources
The SEC wants your thoughts on how it tracks stock market trades using the Consolidated Audit Trail and other data tools. They’re thinking about updating rules to keep up with new tech, privacy, and security needs, and to make sure the system is fair and cost-effective. If you’re involved in the stock market or data tracking, speak up by June 22, 2026!
2026-16781, Self-Regulatory Organizations; New York Stock Exchange LLC; Notice of Filing of a Proposed Rule Change To Amend Sections 303A.00 and 303A.07 of the NYSE Listed Company Manual
The New York Stock Exchange (NYSE) is giving listed companies more time to set up their internal audit teams, which help keep an eye on risks and controls. This change affects all companies listed on the NYSE and aims to make the transition smoother without rushing. No new costs or deadlines are added yet, but companies should prepare for the updated timeline once it’s official.
2026-16784, Self-Regulatory Organizations; The Depository Trust Company; Order Approving Proposed Rule Change To Amend the Redemptions Service Guide and the Operational Arrangements (Necessary for Securities To Become and Remain Eligible for DTC Services)
Previous / Next Documents
Previous: 2025-17924, Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Granting Complainant's Motion To Amend the Complaint and Notice of Investigation
The U.S. International Trade Commission has decided to let a change in a legal complaint about certain drug products with C-Type Natriuretic Peptide variants move forward. This affects companies involved in making or selling these drugs and could impact ongoing investigations or legal actions. No new delays or costs were announced, so things are rolling as planned!
Next: 2025-17926, Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Its Fee Schedule by Revising the Additive Rebate Associated With Securities Priced Below $1.00 in LMM Add Volume Tiers 2-4
Cboe BZX Exchange is updating its fee schedule to change the extra rebate for securities priced under $1.00 in certain volume tiers for Lead Market Makers. This change affects traders dealing with low-priced stocks and kicks in starting September 1, 2025. The update aims to better reward trading activity in these specific tiers without changing other fees.